Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2019

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFIGURE
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 17 Jun 2019 According to a novartis media release, pooled data from SCULPTURE, ERASURE/FIXTURE, TRANSFIGURE, GESTURE, FUTURE 2 and MEASURE 2 studies were presented at the World Congress of Dermatology 2019.
    • 26 Oct 2018 32 week interim analysis results published in the British Journal of Dermatology
    • 30 Nov 2017 Results published in a Novartis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top